Stock Events

Stock Events

PRNAD 

$0.055000
34
+$0.00+0% Friday 20:00

Statistics

Day High
-
Day Low
-
52W High
0.54
52W Low
0.01
Volume
-
Avg. Volume
0
Mkt Cap
996,913.17
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

28AugExpected
Q4 2025
Next
-0.03
-0.02
-0.02
-0.01
Expected EPS
-0.01081752023
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-7.71MNet Income

Analyst Ratings

13.00Average Price Target
The highest estimate is 16.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PRNAD. It's not an investment recommendation.
Apple
5
AAPL
Tesla
4
TSLA
Amazon
4
AMZN
Microsoft
3
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap29.4B
Biogen focuses on neurodegenerative diseases, directly competing with Alterity's focus on Parkinson's and Alzheimer's.
Palatin Technologies
PTN
Mkt Cap17.79M
Palatin Technologies works on novel therapeutics for diseases with a significant unmet medical need, including neurological disorders.
Acadia Pharmaceuticals
ACAD
Mkt Cap4.49B
Acadia Pharmaceuticals specializes in central nervous system disorders, making it a direct competitor in the neurodegenerative disease space.
AnaptysBio
ANAB
Mkt Cap1.97B
AnaptysBio is involved in developing therapeutic antibodies, potentially competing in the neurodegenerative disease treatment market.
Anavex Life Sciences
AVXL
Mkt Cap231.68M
Anavex Life Sciences Corp. focuses on developing drugs for Alzheimer's disease and other central nervous system diseases.
Axsome Therapeutics
AXSM
Mkt Cap12.03B
Axsome Therapeutics develops therapies for central nervous system disorders, including Alzheimer's, directly competing with Alterity.
Ionis Pharmaceuticals
IONS
Mkt Cap9.63B
Ionis Pharmaceuticals develops RNA-targeted therapeutics, including for neurological disorders, competing in the same space as Alterity.
Prothena
PRTA
Mkt Cap483.74M
Prothena Corporation is focused on the discovery and development of novel antibodies for neurodegenerative diseases.
Voyager Therapeutics
VYGR
Mkt Cap207.85M
Voyager Therapeutics focuses on severe neurological diseases through gene therapy, competing in the broader neurodegenerative treatment market.

About

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Show more...
CEO
Country
Australia

Listings

AU
AU
ATH.AU
MU
DE
PBNN.MU
STU
DE
PBN.STU
OTCM
US
PRNAD

0 Comments

Share your thoughts

FAQ

What is PRNAD stock price today?▼
The current price of PRNAD is $0.06 USD — it has increased by +0% in the past 24 hours. Watch PRNAD stock price performance more closely on the chart.
What is PRNAD stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTCM exchange PRNAD stocks are traded under the ticker PRNAD.
What is PRNAD market cap?▼
Today PRNAD has the market capitalization of 996,913.17
When is the next PRNAD earnings date?▼
PRNAD is going to release the next earnings report on August 28, 2026.
What were PRNAD earnings last quarter?▼
PRNAD earnings for the last quarter are -0.03 USD per share, whereas the estimation was -0.02 USD resulting in a -56.52% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is PRNAD revenue for the last year?▼
PRNAD revenue for the last year amounts to 0 USD.
What is PRNAD net income for the last year?▼
PRNAD net income for the last year is -7.71M USD.
In which sector is PRNAD located?▼
PRNAD operates in the Other sector.
When did PRNAD complete a stock split?▼
The last stock split for PRNAD was on January 09, 2023 with a ratio of 1:10.